Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004144 · ClinicalTrials.gov registry record · Phase 1
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00004144 is a Phase 1 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 36 participants.
The verdict
NCT00004144, a Phase 1 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 plus gemcitabine in treating patients who have advanced cancer that has not responded to previous treatment.
Interventions
- DRUG gemcitabine hydrochloride
- DRUG bryostatin 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2000-05 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004144
The ClinicalTrials.gov registry entry for NCT00004144 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00004144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004144 about?
NCT00004144 is a clinical study titled "Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 plus gemcitabine in treating patients who have advanced c...
What is the current status of trial NCT00004144?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2000-05. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00004144?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00004144?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.